Tvardi Therapeutics
TVRD
56 hedge funds and large institutions have $104M invested in Tvardi Therapeutics in 2014 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 14 increasing their positions, 19 reducing their positions, and 11 closing their positions.
27% more capital invested
Capital invested by funds: $81.5M → $104M (+$22M)
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
0% more funds holding
Funds holding: 56 → 56 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
26% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.57M |
| 2 |
California Public Employees Retirement System
Sacramento,
California
|
+$1.19M |
| 3 |
DM
Deerfield Management
New York
|
+$810K |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$716K |
| 5 |
Citigroup
New York
|
+$485K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAM
Aberdeen Asset Management
Aberdeen,
United Kingdom
|
-$7.46M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.15M |
| 3 |
VAM
Visium Asset Management
New York
|
-$881K |
| 4 |
OTPPB
Ontario Teachers' Pension Plan Board
Toronto,
Ontario, Canada
|
-$798K |
| 5 |
MSA
Mason Street Advisors
Milwaukee,
Wisconsin
|
-$532K |
TVRD Hedge Fund Activity: Q4 2014 in Review
56 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q4 2014, worth a combined $104M — up 27% from $81.5M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new TVRD positions and 11 closed out — a net gain of 2 holders — while 14 added to existing stakes and 19 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $2.57M. The largest seller was Aberdeen Asset Management, exiting entirely with an estimated $7.46M sold.
- 56 institutional investors held Tvardi Therapeutics (TVRD) as of Q4 2014, unchanged from Q3 2014.
- Funds reported $104M of Tvardi Therapeutics stock for Q4 2014, up 27% quarter-over-quarter.
- 13 funds opened new Tvardi Therapeutics positions in Q4 2014 and 11 closed out, a net change of +2 holders.
- The largest Tvardi Therapeutics buyer in Q4 2014 was BlackRock Fund Advisors, an estimated $2.57M added.
- The largest Tvardi Therapeutics seller in Q4 2014 was Aberdeen Asset Management, an estimated $7.46M sold.
Based on aggregated 13F filings for Q4 2014.